MedTrace Logo

Clinical Outcomes From Nalmefene

NCT05808881 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2023-07-12

No results posted yet for this study

Summary

The purpose of this study is to assess the effectiveness of nalmefene relative to naloxone for the reversal of opioid intoxication in emergency department (ED) settings.

Conditions

Interventions

DRUG

Nalmefene Hydrochloride Injection

for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration

DRUG

Naloxone Hydrochloride Injection

for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration

Sponsors & Collaborators

  • Purdue Pharma LP

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2024-05-31
Completion
2024-05-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05808881 on ClinicalTrials.gov